Produktname:2,5,6-trichloronicotinic acid
IUPAC Name:2,5,6-trichloropyridine-3-carboxylic acid
- CAS：54718-39-7
- Molekulare Formel：C6H2Cl3NO2
- Reinheit：95%+
- Katalognummer：CM178138
- Molekulargewicht：226.44
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:54718-39-7
- Molekulare Formel:C6H2Cl3NO2
- Schmelzpunkt:-
- SMILES-Code:OC(=O)C1=CC(Cl)=C(Cl)N=C1Cl
- Dichte:
- Katalognummer:CM178138
- Molekulargewicht:226.44
- Siedepunkt:359.1°C at 760 mmHg
- Mdl-Nr.:MFCD02070018
- Lagerung:Store at 2-8°C.
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- Glecirasib
- On January 20, Jacobio Pharma presents data of glecirasib in patients with pancreatic cancer and other solid tumors at the 2024 ASCO GI. For second-line and above KRAS G12C mutated pancreatic cancer patients, the confirmed objective response rate (cORR) was 41.9% and the disease control rate (DCR) was 93.5%. Glecirasib is a potential best-in-class KRAS G12C allosteric inhibitor with promising early clinical efficacy. Glecirasib can be used as monotherapy to treat non-small cell lung cancer, colorectal cancer and other solid tumors with the KRAS G12C mutation. Combinations of Glecirasib with SHP2i, EGFRi, or PD-1 antibodies is expected to have synergistic efficacy and overcome acquired drug resistance.
Suche 
+86 21 5895 0110 
